Beneficial effects of angiotensin II receptor blocker, olmesartan, in limiting the cardiotoxic effect of daunorubicin in rats

Free Radical Research

Volumn 44, Issue 11, 2010, Pages 1369-1377

  Arozal, Wawaimuli ^a,b   Watanabe, Kenichi ^a   Veeraveedu, Punniyakoti T ^a   Thandavarayan, Rajarajan A ^a   Harima, Meilei ^a   Sukumaran, Vijayakumar ^a   Suzuki, Kenji ^c   Tachikawa, Hitoshi ^c   Kodama, Makoto ^c   Aizawa, Yoshifusa ^c  

^a NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

^b UNIVERSITY OF INDONESIA   (Indonesia)

^c NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

angiotensin II receptor blocker; cardiotoxicity; Daunorubicin; olmesartan; oxidative stress

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTHRACYCLINE; DAUNORUBICIN; GELATINASE A; GLUTATHIONE PEROXIDASE; OLMESARTAN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVITY; HEART; HEART FUNCTION; HEART PROTECTION; MALE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; TISSUE LEVEL;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLOTTING, WESTERN; DAUNORUBICIN; HEART; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; MALE; MYOCARDIUM; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; TETRAZOLES;

RATTUS;

EID: 77957962066     PISSN: 10715762     EISSN: 10292470     Source Type: Journal    
DOI: 10.3109/10715762.2010.509399     Document Type: Article

References (38)

1. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56:185-229.
2. Simunek T, Stirba M, Popelova O, Adamcova M, Hridina R, Gersl V. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 2009;61:154-171.
3. Sawyer DB, Fukuzawa R, Arstall MA, Kelly RA. Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexra-zoxane. Circ Res 1999;84:257-265.
4. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007;292:C82-C97.
5. Soga M, Kamal FA, Watanabe K, Ma M, Palaniyandi S, Prakash P, Veeraveedu PT, Mito S, Kumisaki M, Tachikawa H, Kodama M, Aizawa Y. Effects of angiotensin II receptor blocker (candesartan) in daunorubicin-induced cardiomyo-pathic rats. Int J Cardiol 2005;110:378-385.
6. Schwocho LR, Masonson HN. Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. J Clin. Pharmacol 2001;4:515-527.
7. Toko H, Oka T, Zou Y, Sakamoto M, Mizukami M, Sano M, Yamamoto R, Sugaya T, Komuro I. Angiotensin II type 1a receptor mediates doxorubicin-induced cardiomyopathy. Hypertens Res 2002;25:597-603.
8. Nakamae H, Tsumura K, Terada Y, Nakamae M, Ohta K, Yamane T, Hino M. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincris-tine, and prednisolone. Cancer 2005;104:2492-2498.
9. Germanakis I, Anaqnostatou N, Kalmanti M. Troponins and natriuretic peptides in the monitoring of anthracycline cardiotoxicity. Pediatr Blood Cancer 2008;51:327-333.
10. Pouna P, Bonoron-Adele S, Gouverneur G, Tariosse T, Besse P, Robert J. Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardio-toxicity and its circumvention. Br J Pharmacol 1996;117: 1593-1599.
11. Araki S, Hirooka Y, Kishi T, Yasukawa K, Utsumi H, Sunagawa K. Olmesartan reduces oxidative stress in the brain of stroke-prone spontaneously hypertensive rats assessed by an in vivo ESR method. Hypertens Res 2009;32:1091-1096.
12. Kadowaki D, Anraku M, Tasaki Y, Taguchi K, Shimoishi K, Seo H, Hirata S, Maruyama T, Otagiri M. Evaluation for antioxidant and renoprotective activity of olmesartan using nephrectomy rats. Biol Pharm Bull 2009;32:2041-2045.
13. Watanabe K, Ohta Y, Nakazawa M, Higuchi H, Hesegawa G, Naito M, Fuse K, Ito M, Hirono S, Tanabe N, Hanawa H, Kato K, Kodama M, Aizawa Y. Low dose carvedilol inhibits progression of heart failure in rats with dilated cardiomyo-pathy. Br J Pharmacol 2000;130:1489-1495.
14. Gurusamy N, Watanabe K, Ma M, Zhang S, Muslin AJ, Kodama M, Aizawa Y. Dominant negative 14-3-3 promotes cardiomyocytes apoptosis in early stage of type I diabetes mellitus through activation of JNK. Biochem Biophys Res Commun 2004;320:773-780.
15. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC. Measurement of protein using bicinchoninic acid. Anal Biochem 1985;150:76-85.
16. Qin F, Simeone M, Patel R. Inhibition of NADPH oxidase reduces myocardial oxidative stress and apoptosis and improves cardiac function in heart failure after myocardial infarction. Free Radic Biol Med 2007;43:271-281.
17. Robert J. Preclinical assessment of anthracycline cardiotoxic-ity in laboratory animals: predictiveness and pitfalls. Cell Biol Toxicol 2007;23:27-37.
18. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardio-toxicity. Ann Intern Med 1996;125:47-58.
19. de Nigris F, Rienzo M, Schiano C, Fiorito C, Casamassimi A, Napoli C. Prominent cardioprotective effects of third generation beta blocker nebivolol against anthracycline-induced cardiotoxicity using the model of isolated perfused rat heart. Eur J Cancer 2008;44:334-340.
20. Minotti G. NADPH and adriamycin-dependent microsomal release of iron and lipid peroxidation. Arch Biochem Biophys 1990;277:268-276.
21. Dziegiel P, Jethon Z, Suder E, Sopel M, Rabezynski J, Surowiak P. Role of exogenous melatonin in reducing the cardiotoxic effect of daunorubicin and doxorubicin in the rat. Exp Toxicol Pathol 2002;53:433-439. (Pubitemid 34204953)
22. Guzi J, Kusnir J, Marekova M, Chavkova K, Dubayova K, Mojzisova G. Effect of quarcetin on daunorubicin-induced heart mitochondria changes in rats. Physiol Res 2003;52: 773-780.
23. Iqbal M, Dubey K, Anwer T, Ashish A, Pillai KK. Protective effects of telmisartan against acute doxorubicin-induced cardio-toxicity in rats. Pharmacol Rep 2008;60:382-390.
24. Injac R, Boskovic M, Perse M, Koprivec-Furlan E, Cerar A, Djordjevic A. Acute doxorubicin nephrotoxicity in rats with malignant neoplasma can be successfully treated with fuller-enol C60(OH)24 via suppression of oxidative stress. Pharmacol Rep 2008;60:742-749.
25. Ibrahim MA, Ashour OM, Ibrahim YF, El-Bitar HI, Gomaa W, Abdel-Rahim SR. Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity. Pharmacol Res 2009;60:378-381.
26. Sterba M, Popelova O, Simunek T, Mazurova Y, Potacova A, Adamcova M, Kaiserova H, Ponka P, Gersl V. Cardioprotec-tive effects of a novel iron chelator, pyridoxal 2-chlorobenzoyl hydrazone, in the rabbit model of daunorubicin-induced car-diotoxicity. J Pharmacol Exp Ther 2006;319:1336-1347.
27. Harrison DG, Cai H, Landmesser U, Griendling KK. Interactions of angiotensin II with NAD(P)H oxidase, oxidative stress and cardiovascular disease. J Renin Angiotensin Aldos-teron Syst 2003;4:51-61.
28. Dhalla SN, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertens 2000;18:655-673.
29. Valavanidis A, Vlachogianni T, Fiotakis C. 8-hydroxy-2 '-deoxyguanosine (8-OHdG): a critical biomarker of oxidative stress and carcinogenesis. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2009;27:120-139.
30. Elbl L, Hrstkova H, Chaloupka V. The late consequences of anthracycline treatment on the left ventricular function after treatment for childhood cancer. Eur J Pediatr 2003;162: 690-696. (Pubitemid 37255501)
31. Ito H, Miller SC, Billingham ME, Akimoto H, Torti SV, Wade R. Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro . Proc Natl Acad Sci USA 1990;87:4275-4279.
32. Li L, Takemura G, Li Y, Miyata S, Esaki M, Okada H, Kanamori H, Khai NC, Maruyama R, Ogino A, Minatoguchi S, Fujiwara T, Fujiwara H. Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopa-thy. Circulation 2006;113:535-543.
33. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, Martinelli G, Veglia F, Fiorentini C, Cipola CM. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006;114:2474-2481.
34. Chow AK, Cena J, Schulz R. Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature. Br J Pharmacol 2007;152:189-205.
35. Aupperle H, Garbade J, Schubert A, Barten M, Dhein S, Schoon HA, Mohr F W. Effects of autologous stem cells on immunohistochemical patterns and gene expression of metalloproteinase and their tissue inhibitors in doxorubicin cardiomyopathy in a rabbit model. Vet Pathol 2007;44: 494-503.
36. Kizaki K, Ito R, Okada M, Yoshioka K, Uchide T, Temma K, Mutoh K, Uechi M, Hara Y. Enhanced gene expression of myocardial matrix metalloproteinases 2 and 9 after acute treatment with doxorubicin in mice. Pharmacol Res 2006; 53:341-346.
37. Rutschow S, Li J, Schultheiss HP, Pauschinger M. Myocardial proteases and matrix remodeling in infl ammatory heart disease. Cardiovasc Res 2006;69:646-656.
38. Testore F, Milanese S, Ceste M, de Conciliis E, Parello G, Lanfranco C, Manfredi R, Ferrero G, Simoni C, Miglietta L, Ferro S, Giaretto L, Bosso G. Cardioprotective effect of dexrazoxane in patients with breast cancer treated with anthracyclines in adjuvant setting: a 10-year single institution experience. Am J Cardiovasc Drugs 2008;8: 257-263.